People's Justice
The Wire · All news

Depo-Provera shots and brain tumor claims

JAMA Network Open Study Reports 4.5x Meningioma Risk With Medroxyprogesterone

Published Updated

By People's Justice

Couple reading an official-looking letter together at the kitchen table
Illustrative image

What happened

A peer-reviewed study published July 1, 2026 in JAMA Network Open (PMID 42390859) by Hasselblad Lundstrøm N et al. reported a risk ratio of 4.5 for meningioma among users of the contraceptive progestogen medroxyprogesterone, the active ingredient in Depo-Provera. The study, titled 'Contraceptive Progestogens and Incident Meningioma,' adds to a growing body of scientific literature examining the relationship between progestogen-based contraceptives and brain tumor development.

Event date:

Source: pubmed.ncbi.nlm.nih.gov

Depo-Provera shots and brain tumor claims case guideCheck eligibility

Related news

  1. Depo-Provera shots and brain tumor claims

    Global settlement tentatively reached in principle in MDL-3140 (N.D. Fla.) between Pfizer defendants and plaintiffs' lead counsel over Depo-Provera meningioma claims.

    Global settlement tentatively reached in principle in MDL-3140 (N.D. Fla.) between Pfizer defendants and plaintiffs' lead counsel over Depo-Provera meningioma claims. Financial terms NOT disclosed; eligibility and compensation amounts not released; deal pending finalization at the time (Case Management Order No. 14, filed Aug. 10, 2026, later described a settlement agreement dated July 22, 2026 and states no compensation amounts). 5,500+ consolidated cases at announcement (5,830 by July 1, 2026); the MDL case management conference was postponed to late July 2026 while negotiations continue. Source: Drugwatch litigation timeline (consumer legal-news site; no settlement amount is documented anywhere, so none is reported).

    Source: drugwatch.com

  2. Depo-Provera shots and brain tumor claims

  3. Depo-Provera shots and brain tumor claims

    Pfizer Reaches Agreement in Principle to Resolve Federal Depo-Provera MDL

    On June 15, 2026, U.S. District Judge M. Casey Rodgers entered an order noting that Pfizer had reached an agreement in principle with plaintiffs' leadership in MDL 3140 to resolve the federal Depo-Provera meningioma claims. At the time, the agreement was not final and no compensation terms had been disclosed; Pfizer stated it includes no admission of liability and does not affect cases pending in state courts. The court then vacated upcoming bellwether trial deadlines. Case Management Order No. 14 (filed August 10, 2026) later described a settlement program memorialized in an agreement dated July 22, 2026; it states no compensation amounts.

    Source: law360.com